Major histocompatibility complex class I E (HLA-E (in humans); alternatively, MHC class I E)

Major histocompatibility complex class I E (HLA-E) is a non-classical MHC class I molecule present on the surface of most human nucleated cells. Like other class I molecules, HLA-E presents peptides to the immune system, mainly derived from the leader sequences of other MHC class I molecules. HLA-E is recognized by the inhibitory and activating receptors (such as CD94/NKG2A and NKG2C) on natural killer (NK) cells and some T cells, and its peptide-loaded form primarily sends inhibitory signals to NK cells, thus preventing these immune cells from killing healthy self-cells. Its regulatory role in immune surveillance, tolerance, and evasion is particularly relevant in cancer, viral infection, and transplantation. Modulation of the HLA-E pathway is being investigated as a therapeutic strategy to enhance anti-tumor or anti-viral immune responses by blocking its inhibitory interactions with immune checkpoints[1][6][4][2]. **Note**: - HLA-E is a specific, well-characterized, and valid immune therapeutic target; the information above integrates current research and clinical trends. - Variant names (such as MHC-E in non-humans) and closely related molecules exist, but HLA-E is most widely used in the biomedical literature for humans. - The function and roles noted here are based on the broader biology of MHC class I molecules with specific features unique to HLA-E in ligand selection and NK cell recognition[1][2][4][6].

Other names

HLA-E (human leukocyte antigen E)MHC class I EHuman leukocyte antigen class I E

Inhibiting the HLA-E/NKG2A interaction to disinhibit NK cells and cytotoxic T lymphocytes, enhancing anti-tumor or anti-viral immune responses